Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Indian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...

Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...

NVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...

The Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made b...

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglut...

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...

NVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.